The initial observation of Cochrane, Payne, Simpkiss and Woolf, who described the hypoglycemic effect of L-leucine in certain patients with idiopathic infantile hypoglycemia (1), has been repeatedly confirmed. (2-6). L-leucine has also produced a hypoglycemic effect in certain patients with functioning islet cell tumors of the pancreas (7). Not all patients with these clinical syndromes respond to leucine, and the phrase "leucine-sensitive" has been used to designate those patients in whom a hypoglycemic response to leucine can be demonstrated. Previous studies have been unable to demonstrate a lowering effect of L-leucine on blood glucose in normal subjects, and experimental studies of leucine-induced hypoglycemia have of necessity been limited to a few patients with relatively rare diseases. Since hyperinsulinism or hypoglycemia, or both, appeared to be possible necessary prerequisites for the induction of leucine hypoglycemia, an attempt was made to produce experimentally "leucine sensitivity" in normal dogs by pretreatment with insulin. The present report describes the lowering effect on blood glucose that follows L-leucine administration to normal dogs treated with insulin in a variety of ways. In addition, the effect of L-leucine on the magnitude of femoral arteryfemoral vein glucose concentration differences after acute insulin-induced hypoglycemia is discussed.
The initial observation of Cochrane, Payne, Simpkiss and Woolf, who described the hypoglycemic effect of L-leucine in certain patients with idiopathic infantile hypoglycemia (1), has been repeatedly confirmed. (2) (3) (4) (5) (6) . L-leucine has also produced a hypoglycemic effect in certain patients with functioning islet cell tumors of the pancreas (7) . Not all patients with these clinical syndromes respond to leucine, and the phrase "leucine-sensitive" has been used to designate those patients in whom a hypoglycemic response to leucine can be demonstrated. Previous studies have been unable to demonstrate a lowering effect of L-leucine on blood glucose in normal subjects, and experimental studies of leucine-induced hypoglycemia have of necessity been limited to a few patients with relatively rare diseases. Since hyperinsulinism or hypoglycemia, or both, appeared to be possible necessary prerequisites for the induction of leucine hypoglycemia, an attempt was made to produce experimentally "leucine sensitivity" in normal dogs by pretreatment with insulin. The present report describes the lowering effect on blood glucose that follows L-leucine administration to normal dogs treated with insulin in a variety of ways. In addition, the effect of L-leucine on the magnitude of femoral arteryfemoral vein glucose concentration differences after acute insulin-induced hypoglycemia is discussed.
METHODS
Normal mongrel dogs of both sexes were used in these experiments; all were anesthetized with pentobarbital A. Acute administration of crystalline zinc insulin. Glucagon-free insulin, 0.1 U per kg of body weight, was administered to dogs by rapid intravenous inj ection. Blood was withdrawn for glucose determination before the insulin was given and at 15-minute intervals for 2 hours. Paired experiments were done on each animal. On one day animals received insulin plus L-leucine; on another day they were given the same amount of insulin plus saline. Maximum hypoglycemia was observed 30 minutes after the administration of insulin. The degree to which L-leucine prolonged the hypoglycemic response to a standard dose of insulin was calculated by dividing the rise in glucose concentration from 30 minutes to 120 minutes by the fall in blood glucose concentration during the first 30 minutes: per cent recovery = rise in glucose concentration from 30 to 120 minutes/ fall in glucose concentration from 0 to 30 minutes.
B. Acute plus sustained infusion of insulin. A total of 0.3 U of glucagon-free insulin per kg body weight was given to each experimental animal. One-tenth U per kg was given at the beginning of the experiment by rapid intravenous injection, and 0.2 U per kg was given as a sustained infusion over the next 90 minutes. The insulin used for the sustaining infusion was added to 200 ml of either L-leucine or saline in paired experiments in the same animal. Blood was withdrawn for glucose before the insulin was given and every 15 minutes thereafter. After 90 minutes the sustaining infusion of L-leucine plus insulin, or saline plus insulin was stopped, and the animal was permitted to recover from the prolonged period of hypoglycemia during a 60-minute postinfusion period. The degree to which L-leucine prolonged the return of blood glucose concentration to baseline values during this period of recovery was calculated as follows: per cent recovery = rise in glucose concentration during recovery period/fall in glucose concentration during hypoglycemic period.
C. Prior administration of ultralente insulin. Ultralente insulin (0.75 U per kg body weight) was injected subcutaneously into dogs. The animals were anesthetized 14 hours after the injection, blood was drawn for baseline glucose value and, in paired experiments, either L-leucine or saline was administered by rapid intra-654 venous infusion. Blood was then withdrawn for glucose determinations every 15 minutes for 1 hour. The per cent drop in glucose concentration was determined by dividing the value for blood glucose 1 hour after the administration of L-leucine or saline by the initial value.
D. Femoral artery-femoral vein glucose concentration differences after the acute administration of crystalline zinc insulin. The method of these experiments was identical with that described in Section A, except that blood was withdrawn simultaneously from the femoral artery and the femoral vein, rather than from the venous side alone.
RESULTS
Normal dogs, when given an intravenous injection of 0.1 U of glucagon-free insulin per kg body weight, demonstrated a uniform hypoglycemic response. Blood glucose concentration fell to its lowest points 30 minutes after the insulin was given and usually returned to baseline levels by 90 minutes. The concurrent administration of insulin plus L-leucine significantly prolonged the period of hypoglycemia. The degree of prolongation varied from almost complete hypoglycemic unresponsiveness ( Figure 1 ) to varying degrees of delayed recovery of glucose concentration to the initial value. Results in the seven dogs studied are seen in Table I . It is apparent that L-leucine prolonged the period of hypoglycemia in every paired experiment. With a nonparametric sign test (9) , the probability that the effect of L-leucine is due to chance is 0.015.
In order to demonstrate a more pronounced effect with L-leucine, a longer period of hypogly- In an effort to produce a drop in the blood glucose, rather than simply a delayed recovery from hypoglycemia, L-leucine was given to normal dogs 14 hours after subcutaneous injection of ultralente insulin (0.75 U per kg body weight). The experimental results are seen in Table III . It is apparent that none of the dogs was hypoglycemic before either L-leucine or saline was administered. In every paired experiment the administration of L-leucine resulted in a drop in blood glucose concentration. The same volume of the control solution never produced a fall in glucose concentration. With the same nonparametric procedure, the probability that the fall in blood glucose is due to chance rather than L-leucine is 0.0075.
Finally, in an attempt to gain some insight into the mode of action of L-leucine, femoral arteryfemoral vein blood glucose differences were compared for 120 minutes after the intravenous injection of short-acting insulin. The results of four such paired experiments are seen in Table IV . Although arteriovenous glucose differences are usually assumed to reflect peripheral glucose uptake, it has recently been suggested that this is completely true only during periods of rapidly falling glucose concentration, and that during the re- covery phase homeostatic mechanisms come into play, with the result that arteriovenous glucose differences become a function of both hypoglycemic factors (10) . With this thought in mind, we have analyzed the results by dividing the experiment into two periods: 0 to 30 minutes, which corresponds to the period of rapidly increasing hypoglycemia: and 30 to 120 minutes, which represents the recovery period. There is no significant effect of L-leucine on either glucose concentration or on the magnitude of femoral arteryfemoral vein glucose concentration differences during the first 30 minutes, and consequently no evidence that L-leucine acts to increase peripheral uptake of glucose. It is apparent, however, that during the recovery period the administration of L-leucine consistently decreased arteriovenous glucose differences. A mixed model analysis of variants technique (11) showed that the hypothesis that L-leucine diminished arteriovenous glucose differences during the recovery period was significant at the 0.025 level, and barely missed being significant at the 0.01 level. It can also be seen that L-leucine prolonged the return of glucose concentration to the baseline value. The combination of a prolonged recovery period accompanied by smaller arteriovenous glucose differences suggests that L-leucine inhibited the hyperglycemic response to hypoglycemia.
DISCUSSION
The experimental results presented demonstrate that L-leucine is capable of prolonging hypoglycemia produced by short-acting insulin, and of lowering blood glucose concentration following long-acting insulin. The production of "leucine sensitivity" in a series of normal dogs treated with insulin suggests that the hypoglycemic effect of L-leucine is not unique to. any individual, but may represent a physiological effect of L-leucine in a variety of situations characterized by hypoglycemia or hyperinsulinism, or both.
The manner in which L-leucine lowers blood glucose concentration in patients with various hypoglycemic syndromes is still not clear. In this regard Yalow and Berson have demonstrated that hypoglycemia associated with L-leucine administration was accompanied by a rise in plasma insulin levels in four of six patients studied (12) .
Although there is no reason to assume that L-leu-657 cine necessarily acts the same way in man and dog, it is difficult to explain our observations on the theory that L-leucine increases endogenous insulin secretion. Since L-leucine alone has little, if any, effect on glucose concentration of normal dogs, the amount of endogenous insulin being secreted must be quite small. However, when large amounts of exogenous insulin are given to these same dogs, the hypoglycemic effect of L-leucine is quite apparent. It seems unlikely that the concomitant administration of L-leucine plus significant amounts of exogenous insulin would result in greater stimulation of endogenous insulin than does the administration of L-leucine alone. Consequently, the possibility arises that the effect of L-leucine in normal dogs treated with insulin is due to some other mechanism.
If L-leucine does not produce its hypoglycemic effects in normal dogs by stimulating endogenous insulin secretion, it might act either by increasing peripheral uptake of glucose or by inhibiting hepatic glucose output. In these instances the exogenous insulin necessary to demonstrate the hypoglycemic effect of L-leucine in normal dogs would be acting in a permissive role. The observation that L-leucine did not increase arteriovenous glucose differences in dogs during insulin-induced hypoglycemia is evidence against the action of L-leucine to increase peripheral utilization of glucose. Furthermore, L-leucine did not significantly increase glucose uptake when incubated with rat diaphragm ini vitro (13) . Demonstration that L-leucine produces smaller arteriovenous glucose differences as it prolongs recovery from insulin-induced hypoglycemia suggests that L-leucine decreases the hyperglycemic response to hypoglycemia-specifically, hepatic glucose output. Since it 'has been shown that insulin can directly inhibit hepatic glucose output (14) , L-leucine may be simply potentiating this action of insulin. It is also possible that L-leucine may inhibit the effects of glucagon or epinephrine, or both, on the activation of phosphorylase (15) 
